{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:54Z","timestamp":1792581714737,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This article aims to review current evidence on the development, diagnosis, and management of retinal pigment epithelium (RPE) tear during anti\u2013vascular endothelial growth factor (VEGF) therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Literature searches were performed using MEDLINE\/PubMed databases (cut-off date: August 2019).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Three key recommendations were made based on existing literature and clinical experience: 1) Multimodal imaging with color fundus photography, optical coherence tomography, near-infrared reflectance imaging, fundus autofluorescence imaging, optical coherence tomography-angiography, and\/or fluorescein angiography are recommended to diagnose RPE tear and assess risk factors. Retinal pigment epithelium tears can be graded by size and foveal involvement. 2) Patients at high risk of developing RPE tear should be monitored after each anti-VEGF injection. If risk factors worsen, it is not yet definitively known whether anti-VEGF administration should be more frequent, or alternatively stopped in such patients. Prospective research into high-risk characteristics is needed. 3) After RPE tear develops, anti-VEGF treatment should be continued in patients with active disease (as indicated by presence of intraretinal or subretinal fluid), although cessation of therapy should be considered in eyes with multilobular tears.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definitive, some data suggest this link.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003083","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T12:00:44Z","timestamp":1608552044000},"page":"671-678","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY"],"prefix":"10.1097","volume":"41","author":[{"given":"Paul","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Centre for Vision Research, Westmead Institute for Medical Research, the University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Oftalmologica Nacional, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogot\u00e1, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.","family":"Joussen","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014University Medicine Berlin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[{"name":"Eye and Retina Surgeons, Camden Medical Centre, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of M\u00fcnster Medical Center, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Wong","sequence":"additional","affiliation":[{"name":"Unity Health Toronto, St. Michael's Hospital, University of Toronto, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Korobelnik","sequence":"additional","affiliation":[{"name":"Service d'ophtalmologie, CHU Bordeaux, Bordeaux, France;"},{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil","year":"2017","journal-title":"Clin Interv Aging"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"R3-20250607","first-page":"142","article-title":"Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis)","volume":"112","author":"Sarraf","year":"2014","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/IAE.0b013e31828992f5","article-title":"Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy","volume":"33","author":"Sarraf","year":"2013","journal-title":"Retina"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/bjo.65.6.417","article-title":"Tears of detached retinal pigment epithelium","volume":"65","author":"Hoskin","year":"1981","journal-title":"Br J Ophthalmol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.survophthal.2017.03.004","article-title":"Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management","volume":"62","author":"Ersoz","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/eye.2011.146","article-title":"Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD","volume":"25","author":"Gutfleisch","year":"2011","journal-title":"Eye (Lond)"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/aos.12234","article-title":"Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment","volume":"92","author":"Clemens","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/IAE.0b013e3181babda5","article-title":"Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections","volume":"30","author":"Chan","year":"2010","journal-title":"Retina"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/IAE.0b013e31817d5d03","article-title":"Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis","volume":"28","author":"Chiang","year":"2008","journal-title":"Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/IAE.0b013e3180cc2612","article-title":"Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration","volume":"27","author":"Chan","year":"2007","journal-title":"Retina"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874364101408010101","article-title":"Incidence of retinal pigment epithelial tears and associated risk factors after treatment of age-related macular degeneration with intravitreal anti-VEGF injections","volume":"8","author":"Empeslidis","year":"2014","journal-title":"Open Ophthalmol J"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/IAE.0000000000000056","article-title":"Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration","volume":"34","author":"Doguizi","year":"2014","journal-title":"Retina"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1111\/aos.12683","article-title":"Reading the signs: Microrips as a prognostic sign for impending RPE tear development","volume":"93","author":"Clemens","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000439445","article-title":"Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring","volume":"235","author":"Clemens","year":"2016","journal-title":"Ophthalmologica"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/IAE.0b013e3182947811","article-title":"Quantification of retinal pigment epithelium tear area in age-related macular degeneration","volume":"34","author":"Clemens","year":"2014","journal-title":"Retina"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1111\/aos.13052","article-title":"OCT-angiography for assessing risk of retinal pigment epithelium tear in patients with vascular retinal pigment epithelium detachment due to AMD","volume":"94","author":"Clemens","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/IAE.0b013e3181cdf366","article-title":"A new grading system for retinal pigment epithelial tears","volume":"30","author":"Sarraf","year":"2010","journal-title":"Retina"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/sj.eye.6703098","article-title":"Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"23","author":"Gelisken","year":"2009","journal-title":"Eye (Lond)"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/eye.2008.145","article-title":"Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study","volume":"22","author":"Leitritz","year":"2008","journal-title":"Eye (Lond)"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2009.01547.x","article-title":"Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration","volume":"88","author":"Konstantinidis","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.oftal.2016.01.001","article-title":"Anti-VEGF and its impact on the outer retina: retinal pigment epithelium tear after an injection of aflibercept in contralateral eye","volume":"91","author":"Campos Polo","year":"2016","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R34-20250607","first-page":"1199","article-title":"Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection","volume":"8","author":"Fujii","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R35-20250607","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S47735","article-title":"Retinal pigment epithelium tear after intravitreal aflibercept injection","volume":"7","author":"Saito","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R36-20250607","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00347-013-2954-3","article-title":"Tear in the retinal pigment epithelium by intravitreal injection of aflibercept [in German]","volume":"111","author":"Bertelmann","year":"2014","journal-title":"Ophthalmologe"},{"key":"R37-20250607","first-page":"373","article-title":"Tears of the retinal pigment epithelium during aflibercept therapy: PED and treatment characteristics","volume":"5","author":"Carle","year":"2014","journal-title":"J Clin Exp Ophthalmol"},{"key":"R38-20250607","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/eye.1988.22","article-title":"Repair after tears of the retinal pigment epithelium","volume":"2","author":"Chuang","year":"1988","journal-title":"Eye (Lond)"},{"key":"R39-20250607","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00417-002-0505-8","article-title":"Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications","volume":"240","author":"Pauleikhoff","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R40-20250607","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IAE.0000000000002713","article-title":"Suspending treatment of neovascular age-related macular degeneration in cases of futility","volume":"40","author":"Wong","year":"2020","journal-title":"Retina"},{"key":"R41-20250607","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg"},{"key":"R42-20250607","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jfo.2018.04.017","article-title":"Retinal pigment epithelial tears","volume":"42","author":"Sastre-Ib\u00e1\u00f1ez","year":"2019","journal-title":"J Fr Ophtalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:07:21Z","timestamp":1749319641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003083","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}